Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn’s Disease, Ulcerative Colitis), By Drug Class (Aminosalicylates, Corticosteroids, TNF inhibitors, IL inhibitors, Anti-integrin, JAK inhibitors, Others), By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Inflammatory Bowel Disease Treatment Market Size

The global inflammatory bowel disease treatment market size was valued at USD 20.33 billion in 2022. It is estimated to reach USD 27.95 billion by 2031, growing at a CAGR of 3.6% during the forecast period (2023–2031).

A growing number of innovative biological agents and anti-cytokine agents, each with its unique mode of action, are being developed, both contributing to the market's expansion. The term "inflammatory bowel disease" (IBD) refers to conditions where the tissues in your digestive tract have experienced persistent (chronic) inflammation. IBD can have various forms—inflammatory colitis. The lining of the large intestine (colon) and rectum are affected by this disorder, which causes inflammation and sores (ulcers). Reducing the inflammation that leads to the signs and symptoms of inflammatory bowel disease is the aim of treatment. This might reduce the risk of complications, long-term remission, and symptom relief in the best scenarios.

In most cases, surgery or medication therapy is used to treat IBD. In the next years, market growth is predicted to be fuelled by the increasing incidence of ulcerative colitis and Crohn's disease worldwide. A surge in the use of biological medications for the treatment of IBD as well as the presence of potent pipeline candidates like AbbVie's Skyrise (Risankizumab) and Rinvoq (upadacitinib), Lilly's lebrikizumab, Takeda's subcutaneous formulation of Entyvio (vedolizumab), are likely to support the market expansion. Government measures to enhance healthcare for IBD patients have increased, as these individuals are more prone to contracting infections due to immunosuppressive medications.

Inflammatory Bowel Disease Treatment Market Growth Factors

Robust Product Pipeline

A robust product pipeline, consisting of over 616 clinical trials for developing alternative therapy options for IBD, is projected to fuel market expansion. There is no cure for inflammatory bowel disease (IBD) at this time; nevertheless, current therapy concentrates on reducing inflammation, lowering the risk of complications, and achieving long-term remission. Hospitals and other healthcare institutes are conducting clinical trials in close collaboration with pharmaceutical corporations to ensure the patient's well-being.

Antibiotics, immunosuppressants, biologics, and anti-inflammatory medicines comprise the current pharmaceutical class for treating inflammatory bowel disease (IBD). Researchers are now working on developing various targeted medications for treating inflammatory bowel disease (IBD). These products include Janus kinase three inhibitors, selective S1P receptor modulators, human interleukin, and DHODH inhibitors.

Emergence of Biosimilars

The cost of biologicals continues to skyrocket while remaining prohibitively expensive. The anticipation that the patents on certain pharmaceuticals may lapse is one of the driving forces behind the development of new biosimilars. One of the high-impact rendering drivers is the growing application of biosimilars in treating Crohn's disease. Remicade is a biologic medication that was given FDA approval in 1998 and is produced by Janssen Pharmaceuticals, Inc. Most of its applications are in treating ulcerative colitis and Crohn's disease. A growing number of innovative biological agents and anti-cytokine agents, each with its unique mode of action, are being developed, both contributing to the market's expansion.

Market Restraining Factors

Lack of Early Diagnosis

The symptoms of Crohn's disease and ulcerative colitis are a bit of a mystery. Both conditions affect the digestive tract. A correct diagnosis of inflammatory bowel disease (IBD) may be delayed because the symptoms of IBD are similar to those of a wide variety of other conditions. Delayed disease identification can lead to major complications, including an increased chance of intestinal stenosis and other life-threatening disorders. Early identification and treatment of Crohn's disease and ulcerative colitis raises the likelihood of a favorable prognosis and makes it possible to prevent the intestinal damage produced by these diseases.

Market Opportunities

Surging Approval of Biosimilars

Due to the numerous advantages that biosimilars like Hormoz, Reflexes, Imraldi, and Inflector offer over more traditional treatment alternatives, it is anticipated that the adoption of successful medicines will rise. This is a result of more people becoming aware of biosimilars' benefits. More biosimilars have received approval and will shortly be on sale, including Avsola (made by Amgen Inc.), Cyltezo (made by Boehringer Ingelheim), IXIFI (made by Pfizer Inc.), and Hulio (made by Mylan N.V.).

The demand is expected to rise due to the introduction of biosimilars. This is due to the sensitivity of emerging market economies to price changes. The growing acceptance of biosimilars for juvenile Crohn's disease is another factor that will contribute to expanding the global market. This will be a crucial component. The investments made in creating cutting-edge technologies and emerging market growth are additional major factors driving the market's expansion. These elements' potential will help increase the market for conditions that result in colon inflammation.

Regional Insights

North America: Dominant region with 15.27% market share

North America is the most significant global inflammatory bowel disease treatment market shareholder and is estimated to exhibit a CAGR of 15.24% over the forecast period. North America is currently in the driver's seat regarding the market for inflammatory bowel diseases, both in terms of market share and market revenue, and it is projected that this dominance will continue to grow throughout the projection period. This is because an increasing number of people are looking for a particular therapy, and the rising expenses associated with medical care will further accelerate the rate at which this market is expanding. As a result of these two factors, the rate at which this market is expanding is accelerating. In addition, the presence of many key competitors and a high prevalence of inflammatory bowel illnesses such as Crohn's disease and ulcerative colitis will further accelerate the market's growth rate in this particular sector.

Asia Pacific: Fastest growing region with the highest CAGR

Asia-Pacific is anticipated to exhibit a CAGR of 13.94% over the forecast period. The Asia-Pacific region is projected to have the highest growth rate throughout the time covered by the forecast. The growing older population, the increased risk of having inflammatory illnesses, the rising incidence of inflammatory bowel disorders, and the improvement in healthcare policy in the region are some of the primary factors that will contribute to the expansion of the market in the years to come. These factors will all play a significant role in the market's growth. In addition, the increasing consumption of biosimilar products and biologics, as well as the growing investments made by major players in the region, are predicted to fuel the expansion of the market in the not-too-distant future.

In Europe, Countries such as Germany, France, and the United Kingdom make substantial contributions to the market for inflammatory bowel disease (IBD) treatment, which is another significant market for IBD therapy. The number of people diagnosed with inflammatory bowel disease (IBD) in Europe has been steadily increasing, which has led to an increase in the demand for innovative and effective treatment options. The European market is characterized by a varied regulatory environment, with different nations having clearance processes for novel therapies. This diversity in the regulatory landscape is one of the market's defining characteristics. This is because many nations have varying approaches to their respective healthcare systems.

Latin America has been witnessing growth due to improvements in healthcare infrastructure and greater awareness, even though the market for inflammatory bowel disease (IBD) accounts for a lower fraction of the worldwide market overall. Regarding their respective marketplaces, Brazil and Mexico are two of the most important countries in the region that can be found here.

In the Middle East and Africa, although the prevalence of inflammatory bowel disease (IBD) is lower in contrast to that of other regions, there is an increasing desire for innovative treatment alternatives. For the treatment of inflammatory bowel disease (IBD), this part of the world is home to some of the most important markets in the world, including South Africa, Saudi Arabia, and the United Arab Emirates, to name just a few.

Biosimilars Market Segmentation Analysis

By Type

The market is bifurcated into Crohn’s disease and ulcerative colitis. The ulcerative colitis and nutraceuticals segment dominates the global market and is projected to exhibit a CAGR of 4.3% over the forecast period. The category dealing with Crohn's disease held the biggest proportion of the market and is projected to dominate throughout the forecast period. The disease can affect both the small and the large intestine, but the small intestine is where it manifests itself most frequently. A genetic predisposition or a malfunction in the immune system is the primary driver of this disease. Oral and injectable medications, as well as oral and injectable corticosteroids, 5-ASAs, immunomodulators, biologics, biosimilars, and other medications, are among the primary therapy choices for Crohn's disease. One of the primary causes contributing to the segment's expansion is Crohn's disease's rising prevalence and incidence.

By Drug Class

The market is segmented into aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others. The JAK inhibitors dominate the global market and are predicted to exhibit a CAGR of 23.5% during the forecast period. As a result of their participation in the signaling of cytokines and growth factors, AK inhibitors are an essential component in treating immune-mediated diseases. JAK inhibitors are a newer group of pharmaceuticals that are anticipated to experience the quickest growth throughout the projection period due to the releases of new products and the robustness of the product pipeline. It is projected that key biologic manufacturers will focus on expanding the indications for their products to enter the market for the treatment of inflammatory bowel disease in the future, which is expected to be the primary driver of market growth. For example, the medication candidate upadacitinib (Rinvoq) developed by AbbVie, Inc. is now participating in a Phase III clinical study for the treatment of moderately active to severely active inflammatory bowel disease (IBD), and it is anticipated that the drug will be made available for purchase by the year 2024. In addition, prominent organizations are concentrating their efforts on clinical research conducted in conjunction with other businesses to break into the market.

By Route of Administration

The market is bifurcated into injectable and oral. The oral segment owns the highest market share and is predicted to exhibit a CAGR of 5.9% over the forecast period. Most oral medications used to treat Inflammatory Bowel Disease (IBD) are aminosalicylates, corticosteroids, and JAK inhibitors. Amino salicylates are one of the most important oral drug classes to treat IBD, whereas JAK inhibitors are a relatively novel IBD treatment. Consequently, this segment's market share is anticipated to increase over the forecast period. Oral biologics in development, such as upadacitinib, tofacitinib, filgotinib, etrasimod, and ozanimod, are expected to drive segment growth over the forecast period. For instance, Immunic AG is currently enrolling patients to evaluate the efficacy and safety of vidofludimus calcium (IMU-838), a novel DHODH inhibitor, for induction and maintenance therapy in moderate-to-severe ulcerative colitis.

• In addition, Dizal Pharmaceuticals is developing AZD4205, a JAK inhibitor for treating Crohn's disease. Increasing research activities in formulating oral drugs will drive segment growth over the next several years.

By Distribution Channel

The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacy segment is the most significant contributor to the market and is estimated to exhibit a CAGR of 6.5% over the forecast period. Due to the increasing adoption of e-commerce trends and the substantial amount of promotion activities at public platforms concerning online pharmacies, the online pharmacy segment is anticipated to have the quickest development over the projection year. Additionally, the availability of self-administered prefilled syringes and pens at online pharmacies contributes to the movement of customers away from traditional pharmacies and toward their digital counterparts.

The increase in pharmaceutical service providers using online platforms can be attributed to the COVID-19 pandemic. The platform used by internet pharmacies allows for social detachment and guarantees users' protection. This market segment's share of total revenue is expanding due to the growing popularity of online shopping and the increased demand for it. This demand is driven by the comfort, flexibility, and convenience of shopping online.

Recent Developments

• November 2023- Strong results observed for Adalimumab Biosimilar GP2017 for inflammatory bowel disease.
• October 2023- Teva hopes Sanofi's collaboration will lead to a blockbuster IBD drug.